Monitor for future updates on CAPTAIN trial oncologic outcomes and any FDA submission for the Siemens 0.55T platform — these are the next catalysts that could move the stock. No near-term revenue read-through from this filing.
Price Chart
Executive Summary
Profound Medical announced five abstracts presented at the 15th Interventional MRI Symposium, highlighting real-world outcomes from the CARE Registry and Mayo Clinic centers, statistically superior functional preservation from the CAPTAIN randomized trial, and technical feasibility of TULSA on a lower-field-strength Siemens 0.55T MRI platform. The press release contains no financial data, guidance, or regulatory approvals — it is a routine clinical evidence update with no immediate revenue or earnings impact.
Key Facts
- CAPTAIN randomized trial: whole-gland TULSA 2.1x more likely to preserve erectile function and pad-free continence vs robotic RP at 6 months (p=0.004)
- Mayo Clinic Florida (58 patients, up to 4.5 yr follow-up): 100% pad-free continence, 94% leak-free continence, 87.5% preserved erections sufficient for penetration beyond 12 months
- CARE Registry (197 patients, median 24 mo follow-up): median PSA nadir 0.23 ng/mL (whole-gland), 0.60 ng/mL (subtotal), 1.10 ng/mL (focal)
- Technical validation on Siemens 0.55T Free.Max MRI: 40% improved temperature-measurement precision, targeting accuracy 1.0 ± 0.9 mm — not FDA-cleared or commercially available on this platform
- No financial results, revenue, earnings, or guidance provided in the filing
Financial Impact
No financial figures disclosed; clinical evidence update only
Risk Factors
- Technical feasibility on Siemens 0.55T does not establish FDA clearance or commercial availability
- CAPTAIN trial oncologic outcomes are still maturing — functional superiority does not guarantee oncologic non-inferiority
- Single-center and registry data may not generalize to broader clinical adoption
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006615 |
| Document: f8k_101426.htm | 0001171843-26-006615 |
| Document: 0001171843-26-006615-index-headers.html | 0001171843-26-006615 |
| Document: 0001171843-26-006615-index.html | 0001171843-26-006615 |
| Document: 0001171843-26-006615.txt | 0001171843-26-006615 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $5.56 | awaiting T+5 | — | $5.64 (+1.53%) |
Oct 14, 2026 13d ago | 8-K | $6.62 $5.69 | ▼ −14.05% | ▼ −14.50% | $5.64 (−14.73%) |
Oct 9, 2026 18d ago | 8-K | $6.90 $6.01 | ▼ −12.90% | ▼ −10.93% | $5.64 (−18.19%) |
Oct 7, 2026 20d ago | 8-K | $6.91 $6.31 | ▼ −8.68% | ▼ −8.41% | $5.64 (−18.31%) |
Sep 3, 2026 7w ago | 8-K | $6.89 $5.81 | ▼ −15.67% | ▼ −14.47% | $5.64 (−18.07%) |
Sep 3, 2026 7w ago | 8-K | $6.80 $5.97 | ▼ −12.21% | ▼ −11.06% | $5.64 (−16.99%) |
Aug 17, 2026 10w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.64 (−13.82%) |
Aug 17, 2026 10w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.64 (−13.82%) |
Jul 24, 2026 13w ago | 8-K | $7.26 $7.25 | ▼ −0.14% | ▼ −0.51% | $5.64 (−22.25%) |
Jul 15, 2026 14w ago | 8-K | $6.96 $6.99 | ▲ +0.43% | ▲ +1.41% | $5.64 (−18.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers